Top

Callitas Health Inc

OTC Pink | Dec 10, 2019, 10:21 AM EST

MPHMF:US $ 0.078
CHANGE
0.00 (0.00%)
VOLUME
0
Day Low: N/A
Day High: N/A
 Back
Callitas Health Interim President & CEO Will Present at the 2018 Proactive's CEO Investors Forum

CINCINNATI, OH & NEW YORK, NY, May 09, 2018 (GLOBE NEWSWIRE) -- Callitas Health Inc. (CSE: LILY, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “Callitas”) an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, will send Interim President and CEO, James Thompson to the 2018 Proactive’s CEO Investors’ Forum. Mr. Thompson will be a featured presenter, discussing the mission and products of the Company, which focuses on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. 

Bringing together institutional and retail investors, the forum features presentations from biotech CEOs, followed by a casual moderated panel discussion with all the presenters. Attendees will also have a chance to ask the presenters questions during the Q&A session and network with fellow attendees. Along with Callitas, other presenters include Landos Biopharma and Pressure BioSciences Inc. 

“I’m looking forward to sharing Callitas Health’s mission, products and vision with potential investors,” said Thompson. “Not only will this be a great forum to get our name out in the industry, the networking will be helpful to connect with other like-minded companies.”  

The event takes place on Wednesday, May 16, 2018, at the 3 West Club in New York City.

About Callitas Health:

Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive(www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaMint strips and orphan drug technologies. For more information visit www.callitas.com.

Contacts:

Callitas Health:

James Thompson, CEO, or
Callitas Investor Relations
Phone: +1 (859) 868-3131

TraDigitalIR:

Investor Relations – Kevin McGrath, Managing Director

Phone:  +1 (646) 418-7002

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.

Primary Logo

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.